In a single stroke, the deal takes Sun Pharma from being India’s largest drugmaker to a top-tier global pharmaceutical company doubling its annual revenue to $12 billion, increasing its presence to 150 countries, and giving it a 24,000-strong commercial sales force operating on the same field as Pfizer and AstraZeneca. Whether it cements Shanghvi’s legacy as the architect of India’s first truly global pharma major, or whether, after four decades of disciplined wins, it finally tests the limits of his manual, will mould what comes next not just for Sun Pharma—where a new generation is ready to take on more—but also for the Indian pharmaceutical industry. “I’m happy, excited, also a little bit anxious. It is a large transaction that we are entering into,” Shanghvi said at a press conference announcing the deal.